Journal List > Tuberc Respir Dis > v.61(3) > 1000993

Kim, Lee, Lee, Cho, Na, and Han: The Complementary Role of FEV6 in Bronchodilator Reversibility Test for the Old Age

Abstract

Background

In the measurement of bronchodilator reversibility, the forced expiratory volume in one second(FEV1) and the forced vital capacity(FVC) are commonly used parameters and recommended criteria for the reversibility requiring an increase of more than 200ml and 12% above the baseline, respectively. However, aged patients do not often meet the criteria of an increase in volume(>200ml) even though the medical history of that patient is adequate for asthma. This study investigated the role of the forced expiratory volume in six seconds(FEV6) in the bronchodilator reversibility test in elderly patients.

Methods

A total of 236 patients more than 65 years of age with a FEV1/FVC ratio<80% were enrolled in this study. The bronchodilator revesibility tests were examined. With the setting FEV1 as the baseline, the patients were divided into three groups;
Group I : FEV1≧80% of the predicted value,
Group II : 60%<FEV1<80% of the predicted value,
Group III : FEV1≦60% of the predicted value.

Results

Positive reversibility in the FEV1, FEV6, and FVC was in 33(14.0%), 49(20.8%) and 55(23.3%). However, Group III presented with reversibility in the FEV1, FEV6, and FVC in 15(22.4%), 30(44.8%) and 32(47.8%) respectively.

Conclusions

The FEV6 might be used as a complementary parameter in bronchodilatror reversibility in elderly patients. However, more study will be needed to determine the usefulness of FEV6 in bronchodilator reversibility test.

Figures and Tables

Figure 1
Positive reversibility according to the different parameters for each groups of 236 patients
trd-61-227-g001
Table 1
Demographics and clinical characteristics of patients
trd-61-227-i001

Values are mean±standard deviation.

*forced vital capacity, forced expiratory volume in one second, forced expiratory volume in six seconds, §body mass index, changes after bronchodilator reversibility test

Table 2
Clinical characteristics of each groups, subdivided into three groups according to FEV1
trd-61-227-i002

Values are mean±standard deviation.

*forced vital capacity, forced expiratory volume in one second, forced expiratory volume in six seconds, §body mass index, changes after bronchodilator reversibility test

Table 3
Bronchodilator reversibility in FEV6 and commonly used parameters
trd-61-227-i003

Values are number of patients.

*bronchodilator reversibility using FVC and/or FEV1 as parameters,

bronchodilator reversibility using only FEV6 as parameter

The BDR as the gold standard, the measured sensitivity, specificity, positive predictive value, and negative predictive value of FEV6 in reversibility test are 64.3%, 100%, 100%, 95.4% in group I, 50.0%, 97.3%, 83.3%, 87.8% in group II, 38.9%, 86.7%, 63.6%, 70.3% in group III, 50.0%, 97.1%, 80.8%, 88.8% in total, respectively.

Table 4
Bronchodilator reversibility according to the each parameters
trd-61-227-i004

Values are number of patients.

*bronchodilator reversibility using only FVC as parameter, bronchodilator reversibility using only FEV1 as parameter, bronchodilator reversibility only FEV6 as parameter

The reversibility of FVC as the gold standard, the measured sensitivity, specificity, positive predictive value, and negative predictive value of FEV6 in reversibility test are 75%, 100%, 100%, 97.2% in group I, 72.7%, 95%, 80%, 92.7% in group II, 72.7%, 82.4%, 80%, 75.7% in group III, 63.4%, 95.6%, 76.5%, 93.6% in total, respectively.

The reversibility of FEV1 as the gold standard, the measured sensitivity, specificity, positive predictive value, and negative predictive value of FEV6 in reversibility test are 77.8%, 98.2%, 77.8%, 98.2% in group I, 66.7%, 90.5%, 60%, 92.7% in group II, 71.4%, 62.3%, 33.3%, 89.2% in group III, 71.9%, 87.3%, 47.0%, 95.2% in total, respectively.

References

1. Killian KJ, Summers E, Watson RM, O'Byrne PM, Jones NL, Campbell EJ. Factors contributing to dyspnoea during bronchoconstriction and exercise in asthmatic subjects. Eur Respir J. 1993. 6:1004–1010.
2. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005. 26:319–338.
3. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005. 26:948–968.
4. Stoller JK, Buist AS, Burrows B, Crystal RG, Fallat RJ, McCarthy K, et al. Quality control of spirometry testing in the registry for patients with severe alpha1-antitrypsin deficiency: alpha1-Antitrypsin Deficiency Registry Study Group. Chest. 1997. 111:899–909.
5. Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest. 1999. 116:416–423.
6. Swanney MP, Beckert LE, Frampton CM, Wallace LA, Jensen RL, Crapo RO. Validity of the American Thoracic Society and other spirometric algorithms using FVC and forced expiratory volume at 6 s for predicting a reduced total lung capacity. Chest. 2004. 126:1861–1866.
7. Akpinar-Elci M, Fedan KB, Enright PL. FEV6 as a surrogate for FVC in detecting airways obstruction and restriction in the workplace. Eur Respir J. 2006. 27:374–377.
8. American Thoracic Society. Standardization of Spirometry, 1994 update. Am J Respir Crit Care Med. 1995. 152:1107–1136.
9. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest. 1998. 114:1607–1612.
10. Lorber DB, Kaltenborn W, Burrows B. Responses to isoproterenol in a general population sample. Am Rev Respir Dis. 1978. 118:855–861.
11. Dales RE, Spitzer WO, Tousignant P, Schechter M, Suissa S. Clinical interpretation of airway response to a bronchodilator: epidemiologic considerations. Am Rev Respir Dis. 1988. 138:317–320.
12. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986. 133:814–819.
13. Sourk RL, Nugent KM. Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis. 1983. 128:153–157.
14. Enright RL, Connett JE, Bailey WC. The FEV1/FEV6 predicts lung function decline in adult smokers. Respir Med. 2002. 96:444–449.
15. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1/FEV6 and FEV6. Eur Respir J. 2006. 27:378–383.
16. Demir T, Ikitimur HD, Koc N, Yildirim N. The role of FEV6 in the detection of airway obstruction. Respir Med. 2005. 99:103–106.
17. Killian KJ, Watson R, Otis J, St Amand TA, O'Byrne PM. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med. 2000. 162:490–496.
18. Kendrick AH, Higgs CM, Whitfield MJ, Laszlo G. Accuracy of perception of severity of asthma: patients treated in general practice. BMJ. 1993. 307:422–424.
19. Nowak RM, Pensler MI, Sarkar DD, Anderson JA, Kvale PA, Ortiz AE, et al. Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma. Ann Emerg Med. 1982. 11:64–69.
20. Dow L. Asthma in older people. Clin Exp Allergy. 1998. 28:195–202.
TOOLS
Similar articles